Skip to main content
OpenTrials
Completed

NCT Number: NCT02472561

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

The purpose of this study is to understand the effects that a three month lifestyle-based mobile health (mHealth) peripheral artery disease (PAD) prevention program will have on improving physical activity, fitness, important PAD risk factors and quality of life (QOL) in patients with PAD.

By testing a novel mHealth intervention focused on lifestyle modification, this trial will address a critical evidence gap in the care of PAD patients. PAD patients are not eligible for cardiac rehabilitation and therefore struggle with unhealthy lifestyles, and these patients currently have no lifestyle-based care strategies to help them. The results of this study have the potential to lead to new sustainable and resource-efficient, lifestyle-based preventive care strategies for patients with stable PAD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University Medical Center

Durham, North Carolina, 27705, United States

About this study

This is a single-center, randomized trial designed to examine the hypothesis that a lifestyle-based mHealth peripheral artery disease (PAD) prevention program will improve physical activity, fitness, important PAD risk factors and quality of life (QOL).

The investigators may enroll up to 55 men and women being evaluated for leg pain from Duke PAD cardiovascular clinics or after lower extremity angioplasty in the Duke catheterization laboratory. Of the 55 men and women volunteers who may be initially consented, the investigators anticipate a portion (potentially 20%) may drop out during the study timeline, and approximately 45 are expected to complete this study. Following informed consent and baseline testing, the participants will be randomized (1.25:1.00) into either a mHealth (N=25) or usual care group (N=20) [for comparison] for a 12-week period. All patients will be evaluated for walking ability on a treadmill test, quality of life questionnaires, health literacy related to PAD and the most important risk factors specific to PAD (blood glucose if diabetic, daily physical activity and blood pressure).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention
  • A history of stable intermittent claudication for >2 months, and an ABI <0.9 at rest
  • No contraindications to exercise training
  • All subjects will be on the recommended regimen of statin and antiplatelet therapy
  • Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study

Exclusion criteria

  • Present or a past history of gangrene, impending limb loss or osteomyelitis
  • Severe peripheral neuropathy
  • Any condition other than PAD that limits walking for example arthritis or chronic obstructive pulmonary disease (COPD)
  • Unstable angina, history of significant left main disease or three vessel coronary artery disease (>70% stenosis, unprotected by grafts) or recent myocardial infarction (less than eight weeks)
  • Chest pain during treadmill exercise which appears before the onset of claudication, or 2 mm ST depression during exercise regardless of the results of tests for myocardial ischemia
  • Refusal or inability to give informed consent or inability or unwillingness to comply with the study requirements.
  • Dementia that precludes ability to participate in and follow study protocols
  • Enrollment in a clinical trial not approved for co-enrollment.

Treatment and study plan

Fitbit Physical Activity Monitor

Other

Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.

mHealth Glucometer

Other

Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.

Other names: Diabetics Only

mHealth Blood Pressure

Other

Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.

Primary outcomes

  1. Change in cardiovascular fitness level measured by change score analysis of peak Volume of Oxygen (pVO2mL/kg/min) consumption measured during a cardiopulmonary exercise test (CPET).

    Time frame: Baseline and 12-week

    peak VO2 mL/kg/min

Secondary outcomes

  1. Feasibility of this novel mobile health treatment strategy, as measured by patient satisfaction survey

    Time frame: 12-week

    Patient Satisfaction Survey

  2. Implementation of this novel mobile health treatment strategy, as measured by patient satisfaction

    Time frame: 12-week

    Patient Satisfaction Survey

  3. Change in physical activity patterns (steps, time and distance)

    Time frame: Baseline and 12-week

    Steps, time and distance per week

  4. Change score analysis in Body Mass Index measurements

    Time frame: Baseline and 12-week

    Ratio of height to weight

  5. Change score analysis in Blood Glucose measurements

    Time frame: Baseline and 12-week

    Fasting Plasma Glucose and Hemoglobin A1-C

  6. Change in Medication Adherence scores as measured by the Morisky Medication Adherence Scale (MMAS-8)

    Time frame: Baseline and 12-week

  7. Change in Quality of Life (QOL) scores on the Walking Impairment Questionnaire

    Time frame: Baseline and 12-week

  8. Change in Peripheral Artery Disease (PAD) Health Aptitude scores on the Health Aptitude Questionnaire

    Time frame: Baseline and 12-week

  9. Change in Smoking Habits scores on the PAD: Smoking Habit Questionnaire

    Time frame: Baseline and 12-week

  10. Change score analysis in Systolic and Diastolic Blood Pressure measurements

    Time frame: Baseline and 12-week

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • Verizon Wireless

Registry information

Official study title

Verizon mHealth Solution for Elderly Underserved Patients With Peripheral Artery Disease

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jun 16, 2015
Registry last updated
Feb 5, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.